Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

CEOs exercise warrants early, signaling bullish confidence ahead of a key Phase 3 trial data release. Read more here.

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption rates ...

US pharma major Merck & Co (NYSE: MRK) has shared the first results from a late-stage trial of a subcutaneous version of its ...

Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and ...

This phase 3 clinical trial was conducted on over 400 patients with treatment-naive progressive non-small cell lung cancer. Keytruda, launched in 2014, is a representative blockbuster drug that ...

MSD’s subcutaneous (SC) Keytruda (pembrolizumab ... time of two minutes in patients with metastatic non-small cell lung cancer (NSCLC). The therapy also reduced the amount of time patients ...